Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- James Nathanielsz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- 3.33
- Country
- AU
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -27.04
Financials
Net Income
$-8.59MEBITDA
$-8.57MFree Cash Flow
$-1.97MEPS (diluted)
$-12.22Shares Outstanding (diluted)
703.0K-73.6%Operating Expenses
$8.57MCash & Debt
$258.4KReturn of Capital
$499.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-18.86M | $-176.16 |
| 2025 | $0.00 | $-58.92M | $-3712.24 |
| 2024 | $0.00 | $-1.82M | $-0.02 |
| 2023 | $0.00 | $-2.66M | $-26974080.43 |
| 2022 | $0.00 | $-2.66M | $-738454474.53 |
| 2021 | $0.00 | $-2.03M | $-11959986968.33 |
| 2020 | $0.00 | $-4.74M | $-4811228.75 |
| 2019 | $0.00 | $-5.76M | $-164533402928721.25 |
| 2018 | $0.00 | $-7.04M | $-2681095787476315.50 |
| 2017 | $0.00 | $-7.87M | $-16816862437053444.00 |
| 2016 | $0.00 | $-9.41M | $-36225672688644544.00 |
| 2015 | $0.00 | $-3.41M | $-36025722310841640.00 |
| 2014 | $0.00 | $-829.6K | $-21498556576380096.00 |
| 2013 | $0.00 | $-1.44M | $-6.25 |
Valuation
PPCBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·20d ago·Positive
…ta with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer MELBOURNE, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced highlighted new preclinical findings evaluating its pancreatic proenzyme formulation (PRP) alone and in combination with galunisertib (GAL), a small-mo…
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
…pment for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability …
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients "The continued advancement
View source ↗ - Newsglobenewswire.com·27d ago·Positive
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
…a's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, has identifi…
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
…icacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced the publication of a peer-reviewed pilot study in Scientific Reports (Nature Publishing Group) titled “A formulation of pancreatic pro-enzymes provides…
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…c Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recentl…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results "The Company is poised to capitalize on the foundation set
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027.
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
… for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patie…
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
…h for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human (FIH), Phase 1b clinical s…
View source ↗ - Newsglobenewswire.com·102d ago·Positive
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread
View source ↗
Insider trading
Open-market buys and sells by PPCB officers and directors.
- Bought
- $50k
- Sold
- $60k
1 trade
5 trades
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsold
- Nathanielsz James Andrewsolddirector, 10 percent owner, officer: Chief Executive Officer·250,000 @ $0.20·$50k·Sep 4, 2012·filing
- Nathanielsz James Andrewboughtdirector, 10 percent owner, officer: Chief Executive Officer·250,000 @ $0.20·$50k·Aug 23, 2012·filing
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PPCB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
